Insulin Dosage Software Program for People With Type 1 and Type 2 Diabetes

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

46 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Study Completion Date

2011-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine the effectiveness and safety of the computer software program in providing insulin dosage recommendations. Participation in the study for 60 research subjects will last for 16-weeks and includes 3-4 clinic visits and a series of weekly telephone calls from the study team (minimum of 12 calls). Participants will be provided with weekly Study Log Sheets to record their daily blood glucose readings, insulin doses, grams of carbohydrate eaten at each meal (if they have type-1 diabetes) and any changes in their health (e.g., hypoglycemic episodes, illnesses). Participants will fax or drop off a copy of the Study Log Sheet. This information will be entered by the IDC study team into the computer software program. The IDC study team will review the information from the software and, based on the IDC's study team approval, any insulin dose changes will be communicated back to the patient by phone or fax.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diabetes Mellitus Type 2 Basal Insulin Dosing Requirements Study

NCT00874809

Type 2 Diabetes Mellitus

COMPLETED NA

Efficacy and Safety of Frequently Modified Intensive Insulin

NCT01014832

Diabetes

COMPLETED NA

A Study of the Treatment of Type 2 Diabetes With an Insulin Infusion Pump

NCT00115973

Diabetes Diabetes Mellitus, Type 2 Delivery Systems

COMPLETED PHASE1

Feasibility Trial Using an Inpatient Insulin Dosing Calculator

NCT06206525

Diabetes Mellitus, Type 2

COMPLETED NA

Pilot Study Assessing Insulin Pump Therapy in Type 2 Diabetes

NCT00922649

Type 2 Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hygieia, Inc. is developing a device intended for use by insulin-requiring patients with diabetes. It will be a pocket-sized, hand-held device, combining a glucose meter with software that analyzes blood glucose levels recorded in the device's memory, and periodically recommends modifications in insulin dosage. The already developed software algorithms are based on the way an endocrinologist evaluates and frequently adjusts insulin dosage in a patient with diabetes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Insulin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group I

Type 1 diabetes treated with basal-bolus insulin therapy, incorporating carbohydrate-counting and insulin dose software.

Group Type OTHER

insulin dose software

Intervention Type DEVICE

The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.

Group II

Type 2 diabetes treated with basal-bolustherapy and insulin dose software.

Group Type OTHER

insulin dose software

Intervention Type DEVICE

The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.

Group III

Type 2 diabetes treated with biphasic insulin and insulin dose software.

Group Type OTHER

insulin dose software

Intervention Type DEVICE

The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

insulin dose software

The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

blood glucose meter

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* GROUP I
* Have been clinically diagnosed with type-1 diabetes for at least 1-year
* Have an HgbA1c of 7.4% or higher
* Treated with short-acting insulin analog (i.e. HumaLog® Lispro, NovoLog® Aspart, Apidra® Glulisine) before each meal and only one injection of long-acting insulin analog Lantus® (Glargine), per day. Subjects must typically eat 3 meals per day. The total daily combined dose of the long-acting and short-acting insulin analogs must be 25 units or more. Patient must have been using the same insulin regimen for the previous 3-months
* Is currently using an insulin/carbohydrate ratio to decide how much short-acting insulin to take before meals and must be able to use the gram versus choice method of carbohydrate counting.
* GROUP II
* Have been clinically diagnosed with type-2 diabetes for at least 1-year
* Have an HgbA1c of 7.4% or higher
* Treated with short-acting insulin analog (i.e. HumaLog® Lispro, NovoLog® Aspart, Apidra® Glulisine) before each meal and only one injection of long-acting insulin analog Lantus® (Glargine) per day and. Subjects must typically eat 3 meals per day. The total daily combined dose of the long-acting and short-acting insulin analogs must be 25 units or more. Patient must have been using the same insulin regimen for the previous 3-months
* May be using other diabetes agent(s) at a stable dose for the last 3-months.
* GROUP III
* Have been clinically diagnosed with type-2 diabetes for at least 1-year
* Have an HgbA1c of 7.8% or higher
* Take twice daily biphasic Insulin (e.g. HumaLog® Mix 75/25, NovoLog® Mix 70/30) or premixed insulin (i.e. Humulin® 70/30, Novolin® 70/30, NPH/Regular insulin 70/30) with a total daily insulin dose of 25 units and have been using the same insulin regimen for the past 3-months
* May be using other diabetes agent(s) at a stable dose for the last 3-months.

Exclusion Criteria

* Have a history of greater than 2 episodes of severe hypoglycemia in the past year, or have hypoglycemic unawareness when glucose levels are less than or equal to 50 mg/dl
* Have a significant physical, psychological, or cognitive impairment that would prohibit adherence to the protocol
* Have any severe cardiovascular disease including a history of congestive heart failure (New York Heart Association \[NYHA\] 3 or 4), unstable angina, myocardial infarction or stroke that occurred within the 6-months preceding enrollment
* Have known active anemia with a hemotocrit less than 25% in women or 30% in men
* Have known history of renal disease (e.g., serum creatinine level \>2.0 mg/dl or eGFR \< 30 ml/min)
* Have active cancer or cancer in the past 2-years (except non-melanoma skin cancer
* Have history of significant liver disease including cirrhosis or elevated liver enzymes (e.g., AST and ALT greater than 3 times the upper limit of normal values)
* Have a body mass index (BMI) \> 45 kg/m2; and/or
* Are pregnant, plan to become pregnant during the study period, or are breastfeeding.

Minimum Eligible Age

21 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No